What we learn running GTM and capital raises inside health-innovation companies, written down. No gated PDFs, no lead forms. Just the operating notes.
Capital raising
Investors stopped underwriting promise. The round now clears on revenue, conversion evidence, and a pipeline that survives diligence. What that means for how you spend the next twelve months.
Read the note →
Sales engines
The founder-led sales engine outperforms the early sales-leader hire at this stage, and the math is not close. Why hiring feels safe, why it is slow, and what to install instead.
Read the note →
Market entry
A product proven in Europe or Asia does not transfer on its own. The evidence bar, the procurement gauntlet, and the reference problem, and the sequence that gets a foreign product through all three.
Read the note →